Sioux Falls, S.D., tops list of heartworm cities for JulyJuly 15, 2019Sioux Falls, S.D., is the number one city for heartworms in July, the Companion Animal Parasite Council (CAPC) reports.
SPONSORED CONTENTFast Itch Relief for Canine PatientsA treatment for allergic and atopic dermatitis, given just once a day. Visibly improves itch fast. + Learn More Now
Boehringer Ingelheim brand wins international awardJuly 10, 2019Boehringer Ingelheim’s Frontline has been named “Brand of the Year” in the Animalis Edition of the World Branding Awards.
FDA approves ProHeart 12July 8, 2019The U.S. Food and Drug Administration’s (FDA’s) Center for Veterinary Medicine (CVM) has approved ProHeart 12 (moxidectin) extended release injectable suspension for dogs one year and older.
Veterinary Hospitals Association partners with Kindred BioscienceJune 28, 2019Veterinary Hospitals Association (VHA) and Kindred Biosciences have struck up a partnership that will bring the biopharmaceutical company’s products into more than 420 VHA-represented clinics.
Veterinarian pushes for "four-eyes" system in clinicsJune 27, 2019More and more veterinarians are speaking up on how to tackle the high rate of suicide in the veterinary profession.
Proposed race horse bill draws criticism, debateJune 18, 2019A proposed legislation that would establish a uniform national standard for drug restrictions, testing, and enforcement at horse racing venues is receiving pushback from veterinarians and national equine associations.
Aratana Therapeutics' Nocita 10 ml gets FDA approvalJune 13, 2019Aratana Therapeutics announced the U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) has approved an additional vial size (10 ml) of Nocita. "Since its launch in 2016, Nocita has drastically changed veterinary multimodal pain management protocols because it safely and effectively controls pain in patients for up to 72 hours following certain canine and feline surgeries," says Aratana Therapeutics chief development officer, Ernst Heinen, DVM, PhD. "Ultimately, we believe a smaller vial size may allow for expanded use and improve the level of care veterinarians provide for certain painful surgeries." Nocita, which is currently available in a 20-ml vial size, is a local postoperative analgesia for cranial cruciate ligament surgery in dogs and a peripheral nerve block following owner-elected onychectomy (declawing) in cats. The smaller vial size is expected to be made commercially available in fall 2019.
Four bold questions about hand asepsisMay 24, 2019Hand asepsis is one of the most critical components of surgical asepsis to lower the risk of nosocomial diseases. In this column, we answer four critical and bold questions related to hand asepsis. Could you lose your driver's license by scrubbing in? With the emergence of alcohol-based hand-rub solutions (ABHRS), you may be concerned that with repeated use, you could have enough alcohol in your bloodstream to lose your driver's license. Alcohol is indeed absorbed through the skin, and you inhale plenty of it while scrubbing (or "rubbing"). So could a breathalyzer test be positive? A 2006 Australian study1 looked at 20 health-care workers and their use of ABHRS repeatedly over a short period of time: 30 applications in an hour! Then serum and breath ethanol and isopropanol absorption were assessed. Traces of ethanol were detectable in the breath of 30 percent of subjects at one to two minutes after application and in the serum of 10 percent of them at five to seven minutes postexposure. Serum isopropanol levels were undetectable at all time points. Even though ethanol did have a positive result, whether through cutaneous absorption or inhalation of fumes, neither level would be considered positive during a police-issued …
Treat aspiration pneumonia like a bossMay 13, 2019With a 25 percent death rate, aspiration pneumonia should be taken seriously. Treatment traditionally includes hospitalization, IV fluids and antibiotics (often a cephalosporin combined with enrofloxacin), oxygen therapy, nebulization, and coupage.
ISU to begin canine anticancer immunotherapeutic agent clinical trialsFebruary 28, 2019Iowa State University (ISU) College of Veterinary Medicine is starting a clinical study for a new canine anticancer immunotherapeutic. Produced by NovaVive, the anticancer treatment, Immunocidin, has received regulatory approval in the U.S. and Canada to treat mammary tumors. The study will observe dogs with stage I or stage II splenic hemangiosarcoma (HSA) who have undergone a splenectomy to determine the effectiveness of Immunocidin in combination with doxorubicin chemotherapy. Sixty-six dogs will participate in the trial and survival times will be monitored. "Treatment options and survival outcomes for canine HSA have remained essentially stagnant for the past two decades," said Chad Johannes, DVM, DACVIM (SAIM, oncology). "Additional therapeutic options for HSA are needed and we look forward to learning more about how immune stimulation via Immunocidin may play a role in improving outcomes for dogs." Ten oncology clinics will participate in the trial. To find one, visit bit.ly/2D56wBv and enter AAHSD004874 in the keyword search.
